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The legacy manufacturing processes for production of the enzyme products at Genzyme include long-term 
bioreactor perfusion-based cell culture platform. For the process with tight filed ranges and limited 
characterization, a phased approach is being used to improve bioreactor productivity. In the first phase, short-
term process changes that are within filed and historical ranges were implemented. In the second phase, long-
term process improvements that are outside the filed ranges will be implemented for a significant improvement 
in bioreactor productivity.  Results from lab and at-scale study have confirmed that there was no adverse impact 
of phase 2 process improvements on cell culture, downstream processes and product quality. After finalizing the 
regulatory strategy, process validation campaigns to qualify phase 2 process improvements are currently being 
planned.  
 
 
 
 
